SPOTLIGHT: Who's the best CEO of them all?

Who'll brave the pitfalls of generic competition and restless shareholders and pipeline pressure to be the last Big Pharma/Big Biotech CEO standing? That's what the WSJ Health Blog is asking with a new tourney bracket pitting the likes of Pfizer's Jeff Kindler (photo) and Genentech's Arthur Levinson (photo) against one another. Fill in the blanks to reach your own conclusions. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.